Generation Bio Co. (NASDAQ:GBIO) Given Consensus Rating of "Hold" by Brokerages

Shares of Generation Bio Co. (NASDAQ:GBIO - Get Free Report) have received a consensus recommendation of "Hold" from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $8.00.

GBIO has been the topic of a number of analyst reports. Wedbush reaffirmed an "outperform" rating and issued a $5.00 price objective on shares of Generation Bio in a report on Thursday, March 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 price objective on shares of Generation Bio in a report on Wednesday, April 10th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Panagora Asset Management Inc. acquired a new stake in shares of Generation Bio in the 4th quarter worth approximately $49,000. Kestra Private Wealth Services LLC purchased a new position in shares of Generation Bio in the fourth quarter valued at $50,000. SG Americas Securities LLC acquired a new position in shares of Generation Bio during the 3rd quarter worth $51,000. Weiss Asset Management LP purchased a new stake in shares of Generation Bio in the 4th quarter worth about $135,000. Finally, Los Angeles Capital Management LLC grew its stake in Generation Bio by 315.6% in the 4th quarter. Los Angeles Capital Management LLC now owns 275,834 shares of the company's stock valued at $455,000 after acquiring an additional 209,462 shares during the last quarter. 95.22% of the stock is owned by hedge funds and other institutional investors.

Generation Bio Stock Down 3.7 %

GBIO stock traded down $0.11 on Friday, hitting $2.90. The company's stock had a trading volume of 92,056 shares, compared to its average volume of 265,818. The firm has a 50 day moving average of $3.13 and a two-hundred day moving average of $2.21. Generation Bio has a 1 year low of $0.86 and a 1 year high of $6.98.

Generation Bio (NASDAQ:GBIO - Get Free Report) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.12). The business had revenue of $2.88 million during the quarter, compared to analysts' expectations of $3.05 million. Sell-side analysts expect that Generation Bio will post -1.34 earnings per share for the current year.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.